Loading company
Wave Life Sciences, Inc.
WVE · Nasdaq · ·
Next earnings: November 9, 2026
$3.63-1.0%Sep 29 close
- 1M
- -27.0%
- 6M
- -46.9%
- 1Y
- -48.4%
- 5Y
- -41.1%
WVE · Nasdaq · ·
Next earnings: November 9, 2026
$3.63-1.0%Sep 29 close
Wave Life Sciences, Inc. is scheduled to report next on November 9, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2024 | Change |
|---|---|---|---|
| Total Revenue | $2.3M | $19.7M | -88.46% |
| Profit | -$69.4M | -$50.5M | -37.42% |
| Profit per share | -$0.34 | -$0.31 | -9.68% |
| Free Cash Flow | -$54.5M | -$46.3M | -17.59% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Our second quarter performance reflects disciplined execution across the pipeline,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s PRISM ® platform combines multiple modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Wave Life Sciences, Inc.’s Item 2.02 8-K filed July 30, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Wave Life Sciences, Inc. has no earnings call transcript available.